As of the latest Form 4 filed Mar 26, 2025.
What Trevi Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
No Form 4 activity in the trailing 12 months — the table below lists this name’s older filings.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 22 most recent filings for TRVI.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-03-26 | 2025-03-25 | SCIASCIA THOMAS Chief Scientific Officer | SSale | −2.63K | $6.60 | $17.4K | No | Form 4 ↗ |
| 2025-03-26 | 2025-03-25 | SCIASCIA THOMAS, Chief Scientific Officer | MExercise | +2.63K | $1.43 | $3.76K | No | Form 4 ↗ |
| 2025-03-25 | 2025-03-21 | GOOD JENNIFER L President & CEO | SSale | −5.26K | $6.58 | $34.6K | No | Form 4 ↗ |
| 2025-03-25 | 2025-03-21 | GOOD JENNIFER L, President & CEO | MExercise | +5.26K | $1.43 | $7.53K | No | Form 4 ↗ |
| 2025-01-10 | 2025-01-08 | Delfini Lisa Chief Financial Officer | MExercise | +5.00K | $0.51 | $2.56K | No | Form 4 ↗ |
| 2025-01-10 | 2025-01-07 | Delfini Lisa, Chief Financial Officer | MExercise | +1.00K | $0.51 | $511.00 | No | Form 4 ↗ |
| 2024-09-09 | 2024-09-09 | GOOD JENNIFER L President & CEO | SSale | −1.84K | $3.04 | $5.59K | No | Form 4 ↗ |
| 2024-09-09 | 2024-09-09 | GOOD JENNIFER L, President & CEO | MExercise | +1.84K | $1.43 | $2.63K | No | Form 4 ↗ |
| 2024-09-09 | 2024-09-06 | GOOD JENNIFER L, President & CEO | SSale | −4.22K | $3.03 | $12.8K | No | Form 4 ↗ |
| 2024-09-09 | 2024-09-06 | GOOD JENNIFER L, President & CEO | MExercise | +4.22K | $1.43 | $6.03K | No | Form 4 ↗ |
| 2024-08-29 | 2024-08-27 | Meeker David P Director | SSale | −4.55K | $2.93 | $13.4K | No | Form 4 ↗ |
| 2024-08-29 | 2024-08-27 | Meeker David P, Director | MExercise | +4.55K | $1.43 | $6.51K | No | Form 4 ↗ |
| 2024-08-21 | 2024-08-19 | SCIASCIA THOMAS Chief Scientific Officer | SSale | −16.5K | $2.96 | $48.9K | No | Form 4 ↗ |
| 2024-08-21 | 2024-08-19 | SCIASCIA THOMAS, Chief Scientific Officer | MExercise | +16.5K | $1.43 | $23.6K | No | Form 4 ↗ |
| 2024-08-16 | 2024-08-16 | SCIASCIA THOMAS Chief Scientific Officer | SSale | −18.7K | $2.76 | $51.4K | No | Form 4 ↗ |
| 2024-08-16 | 2024-08-16 | SCIASCIA THOMAS, Chief Scientific Officer | MExercise | +18.7K | $1.43 | $26.7K | No | Form 4 ↗ |
| 2024-08-16 | 2024-08-15 | SCIASCIA THOMAS, Chief Scientific Officer | SSale | −12.7K | $2.79 | $35.5K | No | Form 4 ↗ |
| 2024-08-16 | 2024-08-15 | SCIASCIA THOMAS, Chief Scientific Officer | MExercise | +12.7K | $1.43 | $18.2K | No | Form 4 ↗ |
| 2024-08-16 | 2024-08-14 | SCIASCIA THOMAS, Chief Scientific Officer | SSale | −100.00 | $2.75 | $275.00 | No | Form 4 ↗ |
| 2024-08-16 | 2024-08-14 | SCIASCIA THOMAS, Chief Scientific Officer | MExercise | +100.00 | $1.43 | $143.00 | No | Form 4 ↗ |
| 2024-05-31 | 2024-05-29 | SCIASCIA THOMAS Chief Scientific Officer | SSale | −53.4K | $2.55 | $136K | No | Form 4 ↗ |
| 2024-05-31 | 2024-05-29 | SCIASCIA THOMAS, Chief Scientific Officer | MExercise | +59.4K | $2.19 | $130K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also TRVI’s full analysis or the market-wide insider trading feed. The tabs above jump to TRVI’s other SEC data.
Source: SEC Form 4 filings for TRVI, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.